On Thursday, Shares of AbbVie Inc (NYSE:ABBV), lost -0.72% to $60.55.
AbbVie, declared data from the SURVEYOR studies of its investigational HCV regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, that show high rates of sustained virologic response at 12 weeks post-treatment (SVR12) in non-cirrhotic patients with chronic hepatitis C virus (HCV) infection. After 12 weeks of treatment, SVR12 rates achieved were 97-100 percent in genotype 1 (GT1), 96-100 percent in genotype 2 (GT2) and 83-94 percent in genotype 3 (GT3) patients. These data are being presented at The Liver Meeting® 2015, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.
Separately, in a late-breaking presentation of the SURVEYOR-I study, data show non-cirrhotic GT1 chronic HCV patients who received a shorter duration of treatment for 8 weeks with ABT-493 and ABT-530 achieved a SVR12 rate of 97 percent.4
“These results are encouraging and contribute to scientific knowledge about the potential for pan-genotypic options for treating chronic hepatitis C,” said Fred Poordad, M.D., vice president of Academic and Clinical Affairs at The Texas Liver Institute in San Antonio. “These data mark another important step in the continued research to assist address the unmet needs of patients and the medical community.”
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants.
Shares of Aramark (NYSE:ARMK), declined -0.92% to $32.34, during its last trading session.
Aramark, stated strong fourth quarter and full-year fiscal 2015 results which generated a 13% improvement in full year adjusted net income. The company offered an initial outlook for fiscal 2016, and also declared approval by the Board of Directors of a 10% improvement in the company’s regular quarterly dividend.
Aramark provides food, facilities, and uniform services to education, healthcare, business and industry, sports, leisure, and corrections clients primarily in North America. The company offers managed services, counting dining, catering, food service administration, convenience-oriented retail operations, grounds and facilities maintenance, custodial, energy and construction administration, and capital project administration.
Finally, Shares of Qunar Cayman Islands Ltd (NASDAQ:QUNR), ended its last trade with -8.62% loss, and closed at $35.08.
Qunar Cayman Islands Limited, declared that it will report its financial results for the third quarter ended September 30, 2015, after the U.S. market closes on November 24, 2015. Qunar’s administration will hold an earnings conference call at 9:00 PM on November 24, 2015, U.S. Eastern Time (10:00 AM on November 25, 2015, Beijing/Hong Kong Time).
Qunar Cayman Islands Limited operates an online travel commerce platform in the People’s Republic of China. The company through its platform provides a range of travel products comprising flight tickets, hotels, vacation packages, and attraction tickets, in addition to display advertising, train tickets, car services, smart lodging, and other services.